KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Non-Current Deffered Revenue (2019)

Xenon Pharmaceuticals (XENE) has disclosed Non-Current Deffered Revenue for 4 consecutive years, with $709000.0 as the latest value for Q4 2019.

  • Quarterly Non-Current Deffered Revenue changed N/A to $709000.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $709000.0 through Dec 2019, changed N/A year-over-year, with the annual reading at $709000.0 for FY2019, N/A changed from the prior year.
  • Non-Current Deffered Revenue for Q4 2019 was $709000.0 at Xenon Pharmaceuticals, up from $164000.0 in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $709000.0 in Q4 2019, with the low at $164000.0 in Q2 2015.